Gefitinib and erlotinib (Figure 1) are first-generation EGFR inhibitors that have been approved for the treatment of advanced NSCLC with activating mutations in the EGFR tyrosine kinase domain mainly: L858R (EGFRL858R).11–14. This evidence concerns the gene EGFR and non-small cell lung carcinoma.